Mr. Wang is a international partner of Haiwen & Partners Hong Kong Office.  He specializes in the fields of Hong Kong capital markets (both ECM and DCM), cross-border PE investments and mergers and acquisitions.  Mr. Wang often represents Chinese state-owned and private enterprises as well as securities and investment houses in Hong Kong IPOs, international bond issues and cross-border investments and acquisitions.  He has also accumulated rich experience in prospectus drafting for Hong Kong IPO transactions.

Mr. Wang joined Haiwen in 2023 as a international partner.  Previously, he worked as a partner at Herbert Smith Freehills LLP and senior associate at Clifford Chance LLP, respectively.  He is currently based in Beijing, after working in Hong Kong and New York, respectively. Before joining Haiwen, Mr. Wang has been a partner at Herbert Smith Freehills for seven years.

In the area of Hong Kong ECM, Mr. Wang acted as the international counsel for either the issuer or the underwriters in the Hong Kong IPOs of a number of Chapter 18A innovative biotech companies (Acotec Scientific, HeartCare Medical, 3D Medicines, Shanghai Junshi Biosciences, SinoMab BioScience), as well as the Hong Kong IPOs of Linmon Pictures, JL MAG Rare-Earth, NewbornTown Tech, UJU Media, SF Intra-City, New Oriental, Cangnan Instruments, Inner-Mongolia Yitai Coal, Jinzhou Bank, Huadian Fuxin Energy, Chinalco, China Minsheng Bank, Dongfeng Motors, Greentown China, China Construction Bank and ICBC, among others, and led prospectus drafting in many of the above-mentioned deals. Sponsors and underwriters of these deals included top-tier international and PRC investment banks.

In the area of international DCM, Mr. Wang acted as the international counsel for the issuer in the USD, EUR or RMB bond issues or the establishment of, and drawdowns under, mid-term notes programmes of State Grid of China, China BlueStar, Yankuang Energy Group, Huaneng Group, Beijing Gas, ICBC, China Merchants Bank and Sinar Mas Group, among others. The bonds issued were listed on the Hong Kong Stock Exchange, Singapore Stock Exchange, EuroNext Dublin or Luxembourg Stock Exchange, as the case may be.

In the area of cross-border PE investments and M&A, Mr. Wang advised CITIC PE in its acquisition of 100% equity interest in Acotec Scientific, investment as a lead investor in the pre-IPO round financing of MicroPort CardioFlow Medtech, and exit from Sinovent; advised Beijing Auxin Chemical in its acquisition of an Australian company specialized in mining explosives; and advised Beijing Capital AgriBusiness and CITIC Agriculture Industrial Fund in their acquisition of 100% equity interest in Cherry Valley Farms (UK).

Mr. Wang received an LL.B. from Peking University Law School and an LL.M. degree from each of University College London and Stanford Law School.

Chinese, English